New research indicates that the use of Fidaxomicin can help reduce the risk of a C. diff infection relapse, compared to the more popular drug, vancomycin.
Every year, thousands of patients contract C. diff infections in hospitals. These infections are caused by the Clostridium difficile bacteria, and are dangerous infections that can even be fatal. Out of the thousands of patients who suffer these infections every year, approximately 25% who have been treated with vancomycin go on to suffer a relapse of the infection. However, in comparison, persons who are on the Fidaxomicin antibiotic program were much less likely to suffer a relapse.
New research that has just been published in The Lancet, found that only 13% of patients who suffered from these infections and were treated with Fidaxomicin suffered a relapse within 28 days. In comparison, more than 27% who had been treated with vancomycin developed a recurrent infection.
Recently, the Centers for Disease Control and Prevention admitted that the number of hospital-acquired C. diff infections has spiked in recent years. The infection causes symptoms that range all the way from diarrhea to severe inflammation of the colon. Hospitals have typically been found to be the sources of these infections.
According to the Centers for Disease Control and Prevention, it has seen an increase in the number of patients admitted to hospitals with the infection, and also an increase in the number of patients contracting these infections from outpatient centers, doctor’s clinics and ambulatory surgical centers. Hawaii medical malpractice attorneys are very concerned about the increasing number of infections that are contracted at outpatient centers.
People who have recently been on an antibiotics program are at a higher risk of C. diff infections, which is why doctors recommend that patients be urged to complete their antibiotic course, and be monitored for symptoms of diarrhea while on the drugs.